The elucidation of BRAF V600 mutations and the dysregulated RAS/RAF/MEK/ERK pathway in melanoma cells has led to the development of targeted therapies including BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi), which have shown significant efficacy in melanoma eradication and been approved by the Food and Drug Administration (FDA). Here, BRAF is linked to melanoma.